News

Nationwide recall of over 70,000 eye care products due to safety risks prompts consumers to return items for full credit.

Discover how real-world evidence shapes cataract surgery practices, highlighting user satisfaction with enhanced monofocal IOLs at the 2025 ASCRS Annual Meeting.

Almeida highlighted the increasing prevalence of diabetic macular edema and the importance of developing safe, well-tolerated treatments.

Carl D. Regillo, MD, shares insights on the VERONA trial of EYP-1901 at the Retina World Congress 2025 meeting held in Fort Lauderdale, Florida.

Discover how dropless cataract surgery enhances patient comfort and outcomes, reducing the need for eye drops and improving recovery efficiency.

At Retina World Congress 2025, Dilsher S. Dhoot, MD, shares updates on the HELIOS trial and the potential future of tyrosine kinase inhibitors (TKIs)

Researchers uncover corneal changes in multiple myeloma patients treated with belantamab mafodotin, revealing potential impacts on vision and ocular health.

This large database study explored the link between autoimmune problems and AMD.

In this conversation, Franklin discussed a research study on intraoperative fluorescein angiography in surgical procedures, highlighting significant advancements in surgical visualization and patient outcomes.

Perfuse Therapeutics reveals promising results for PER-001, a groundbreaking glaucoma treatment, enhancing vision and ocular health in clinical trials.

Glaucoma management is shifting toward earlier, drop-sparing interventions using sustained drug delivery and advanced laser technologies that improve outcomes and quality of life for both patients and physicians.

Optigo Biotherapeutics presents promising preclinical data at ARVO.

Alkeus Pharmaceuticals reveals promising Phase 2 SAGA study results, showing gildeuretinol slows vision decline in geographic atrophy linked to AMD.

Innovent Biologics initiates phase 2 trial for efdamrofusp alfa, a promising treatment for diabetic macular edema, aiming to improve patient outcomes.

Beacon Therapeutics reveals promising interim results for laru-zova, a gene therapy showing potential to improve vision in XLRP patients.

Machine learning algorithms enhance retinopathy of prematurity screening using smartphone images, expanding access in low-resource settings and easing pediatric ophthalmologist workloads.

The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD.

Galimedix Therapeutics advances GAL-101, an oral therapy targeting Alzheimer’s and AMD, completing phase 1 SAD study with promising safety results.

Exploring how oral sedation and office-based surgery can enhance efficiency and patient experience

A one-drop, low dose atropine study assesses accommodative amplitude and dynamics, with clinically applicable findings.

Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in healthcare.

Isarna Therapeutics reveals promising Phase 2 BETTER trial results for ISTH0036, a potential breakthrough in treating retinal fibrosis.

A study reveals that repeated anti-VEGF injections for AMD do not alter retinal vascular metrics over time, ensuring treatment stability.

In cases with optic nerve hyperfluorescence or neurologic symptoms, prompt neuroimaging is warranted to rule out neuro-Behcet disease and guide multidisciplinary management.